Overview

Sutimlimab (BIVV009) for the Adult Participants With Cold Agglutinin Disease (CAD) Who Have Completed Phase 3 Studies (CARDINAL or CADENZA) in Japan

Status:
Not yet recruiting
Trial end date:
2022-08-03
Target enrollment:
Participant gender:
Summary
This is a multi-center, single treatment-group, open-label study to provide sutimlimab to the adult participants with cold agglutinin disease (CAD) who have completed the CARDINAL or CADENZA studies, and benefitted from sutimlimab treatment in Japan. • Study and treatment duration: the period between the participant's completion of the CARDINAL and CADENZA studies and sutimlimab or other appropriate CAD therapy becoming commercially available to participants in Japan.
Phase:
Phase 3
Details
Lead Sponsor:
Sanofi